Substance / Medication

Pipobroman

Overview

Active Ingredient
pipobroman
RxNorm CUI
8347

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
Kiladjian Jean-Jacques, Chevret Sylvie, Dosquet Christine et al. · J Clin Oncol · 2011
PMID: 21911721Observational
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian Jean-Jacques, Rain Jean-Didier, Bernard Jean-Francois et al. · Semin Thromb Hemost · 2006
PMID: 16810617Observational
Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma.
Cassius Charles, Pages Cécile, Roux Jennifer et al. · J Invest Dermatol · 2016
PMID: 26854489Case Report
Cytogenetic response to pipobroman in Philadelphia-positive chronic myeloid leukemia with thrombocythemic onset.
Orlandi Ester, Bernasconi Paolo, Boni Marina et al. · Ann Hematol · 2005
PMID: 15378276Case Report
Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
Sironi Maria, Bertola Giorgio, Lodato Antonio et al. · Acta Haematol · 2003
PMID: 12714827Case Report
Bone marrow aplasia after pipobroman: an immune-mediated mechanism?
Triffet A, Straetmans N, Ferrant A · Br J Haematol · 2001
PMID: 11736962Case Report
Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
Passamonti Francesco, Lazzarino Mario · Leuk Lymphoma · 2003
PMID: 14565648Review
Pipobroman gets regulatory approval outside Germany.
Tsamaloukas Antonis G · Dtsch Arztebl Int · 2008
PMID: 19633773OtherFull text (PMC)
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.
Passamonti Francesco, Rumi Elisa, Malabarba Lucia et al. · Ann Hematol · 2004
PMID: 15175894Other
Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.
Kiladjian Jean-Jacques, Gardin Claude, Renoux Michel et al. · Hematol J · 2003
PMID: 12764352Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pipobroman (substance)
SNOMED CT
24823004
UMLS CUI
C0031965
RxNorm CUI
8347

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.